FIH Clinical Investigation of Graphene Electrodes for Brain Mapping
Summary
The completed enrollment phase of INBRAIN Neuroelectronics' first-in-human study of their graphene cortical interface at Salford Royal Hospital, Manchester. Ten patients recruited, eight surgically treated during brain tumor resection procedures with no device failures. The graphene electrodes demonstrated superior signal fidelity to conventional metal electrodes and decoded speech patterns at high resolution in awake surgery cases. The study is now in 90-day follow-up; full results expected Q3 2026.
Why it matters
INBRAIN's FIH study is the first completed human safety study for graphene-based neural interfaces in history. The zero-failure, high-fidelity signal quality result from eight patients provides the foundational safety and performance data for INBRAIN's next step: a chronic implant DBS study that uses graphene's simultaneous recording-and-stimulation capability to enable closed-loop therapy impossible with conventional metal leads.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial